INTRODUCTION
Over the last few years, there has been a reevaluation of the role of insulin and insulin growth factors in brain functions. This re-evaluation has been driven by a number of observations and hypotheses that encompass the control of feeding and adiposity, the impact of diabetes on the brain and more recently, the interactions among insulin, diabetes, Alzheimer's disease, and amyloid deposition. Several recent reviews have addressed the role of brain insulin in the control of metabolism and food intake (Gerozissis 2003 . Among several recent reports that support such a role of insulin is the demonstration that mice with conditional knockout of insulin receptors in the brain are overweight, insulin resistant, and glucose intolerant (Bruning et al., 2000) . Furthermore, blockade of hypothalamic insulin receptors by antisense oligonucleotides produced hyperphagia, insulin resistance, and weight increase (Obici et al., 2002) . These examples clearly'show that the brain insulin plays an important role in feeding, peripheral metabolism, and weight regulation. Recent evidence of a down-regulation of brain insulin receptors in obesity and diabetes suggest that insulin resistance may also involve the brain (Mielke, 2005) .
The aim of this review is to put together various recent data that describe the possible role of insulin, insulin receptors, and insulin growth factors in learning and memory. The role of insulin-related peptides is examined in the context of aging, diabetes, and Alzheimer's disease The general hypotheses that are entertained in this review are that 1. type 2 diabetes and obesity lead to insulin resistance in the brain, 2. insulin resistance leads to cognitive impairments in older diabetic patients and 3. insulin resistance increase amyloid deposition in Alzheimer's disease patients.
We first examine what is known about insulin's access to the brain and the impact of diabetes on the transfer of insulin from blood to the brain. We then present a brief summary of the results of studies that examined the interactions between diabetes, aging, and brain with reference to recent reviews for an in-depth analysis of the neurocognitive deficits in type 2 diabetes Messier, 2003; Messier et al., 2004) .
Following this, we review studies that have tested the ability of insulin to modulate brain functions with a particular attention to learning and memory.
For an in-depth review of the role of insulin in metabolism, feeding, and weight control, the reader can consult several excellent reviews (Gerozissis 2003 . Woods, et al., 2003 . Because insulin and insulin growth factor (IGF-I) partially share receptor activity and interact under certain circumstances, we briefly discuss several aspects of IGF-I in the adult and the aging brain. Finally, we examine the interaction of insulin and IGF-I with amyloid deposition and processing as a possible mechanism in the deleterious effect of diabetes on Alzheimer's disease progression. We now turn to the examination of the source of insulin in the brain.
INSULIN TRANSPORT THROUGH THE BLOOD-BRAIN BARRIER
As discussed by Banks (2004) , the nature of insulin resistance in the brain remains unclear. In the periphery, most insulin resistance is associated with receptor or post-receptor effects in specific tissues. In the brain, insulin resistance can manifest itself through changes in brain insulin uptake and by changes in the insulin receptor function as well. To understand these changes, we will briefly review what is known about the transport of insulin through the blood-brain barrier.
The mechanisms by which insulin gains access to the CNS have recently been reviewed (Banks 2004 This level is consistent with the observation that the olfactory bulb has the highest concentration of insulin (Baskin et al., 1987) .
Evidence also suggests that insulin is released in the hypothalamic extracellular space in anticipation of a scheduled meal in rats. Such insulin release is independent of blood insulin levels, showing that certain brain regions can release insulin in relation to a learned association (Orosco et al., 1995) . Additionally, a microdialysis study showed that intra-hypothalamic infusion of glucose increases extracellular insulin and that aging and obesity significantly reduce the glucosemediated insulin release (Gerozissis et al., 2001 Therefore, any theories involving brain insulin resistance will have to take into account not only the regional variations in transport mechanisms but also the concentrations of insulin and insulin receptors in the brain. As a result, insulin resistance in the brain could be due to changes in the receptor-based insulin carrier that would lead to reduced access of insulin to the brain or could be due to changes in insulin receptor function within the brain. One also has to take into account the large variations in blood insulin levels that follow ingestion of food and the feedback-related inhibition of insulin transport during hyperglycemia. We now turn to the effect of diabetes and aging on insulin transport and receptor function.
Hyperglycemia (in normal animals), obesity, and obesity-induced diabetes (in Zucker rats) decrease insulin transport into the brain (Banks et al., 1997a -b. Baskin et al., 1985 . Kaiyala et al., 2000 . Consistent with decreased insulin transport, obese Zucker rats have reduced brain levels of insulin (Baskin et al., 1985) . However, in streptozotocin-or alloxan-induced diabetes, an increase in insulin transport to the brain occurs that is associated with the very low systemic insulin levels in these models. Such low levels of insulin result from the destruction of pancreatic beta cells.
In animals, insulin receptors are highly expressed during development but decline during aging (Zhao et al., 1999 (Abbott et al., 1999) and showed that insulin can rapidly recruit GABAA receptors from the intracellular pool to the post-synaptic domain, suggesting a role for insulin in neural plasticity (Wan et al., 1997) . Similarly (Soininen et al., 1992) . Finally, in normal aged humans, memory and hippocampal volume were found to be correlated to measures of glucose tolerance (Convit et al., 2003 (Wechsler 1981) (Bucht et al., 1983 . Craft et al., 1993 . Craft et al., 1996 1998), others did not (Fujisawa et al., 1991 . Kilander et al., 1993 . Two studies found that compared with ApoE2 bearers, bearers of the ApoE4 allele tend to have lower insulin levels (Craft et al., 1998 . Gonzalez et al., 1999 (Kopf & Baratti 1995 .
One experiment, however, showed that insulin injected in conjunction with glucose improved memory in rats (Messier & White 1987) . Similarly, the peripheral injection of small doses of insulin reversed the amnesia produced by scopolamine in a food-motivated operant task (Blanchard & Duncan 1997 . Messier & Destrade 1994 . Intracerebroventricular injection of insulin was shown to improve the performance on an avoidance task (Park et al., 1995) , although no effect on memory was found following intrahippocampal insulin injection in rats (Paulus et al., 2005) .
The observations that insulin, insulin receptors, and C-peptide levels in cerebral spinal fluid (CSF) appear to be reduced in aging, (Frolich et al., 1998) along with the finding that Alzheimer's patients have lower levels of insulin in the CSF (Craft et al., 1998) suggest impaired transport of insulin into the CSF. The results of these studies have prompted several studies examining the effect of insulin in young and old persons.
The effect of insulin on brain function in humans has been studied using two experimental protocols. In the first, the hyperinsulinemic clamp procedure, increased blood insulin levels are maintained while glucose is infused intravenously to keep blood glucose levels close to normal fasting levels. One study showed that verbal memory is improved in Alzheimer's patients but not in normal age-matched controls during the hyperinsulinemic clamp procedure (Craft et al., 1996) .
A second study that also used the hyperinsulinemic clamp showed that insulin improves the memory of younger patients for emotional words, and also produces changes in the evoked potentials P300 latencies, suggesting an influence of insulin on attentional-cognitive functions (Kern et al., 2001 ). Another study examined the impact of different blood insulin levels using the hyperinsulinemic clamp in Alzheimer patients and aged-matched controls. Patients homozygotic for the APOE4 genotype and healthy controls had better recall at the low insulin levels (150 pmol/L), whereas patients with no APOE4 alleles had better recall at higher insulin levels (219 pmol/L) (Craft et al., 2003) , suggesting a dose-response curve specific for each population.
In an FDG-PET study using the euglycemic clamp, the effect of insulin together with a glucose infusion produced an increase in cerebral glucose uptake (Bingham et al., 2002) . In this study, somatostatin was given to suppress endogenous insulin secretion, and intravenous glucose was used to keep blood glucose levels at 5 mmol/L. Little glucose was infused in the control condition, but an average of 292.45 mg/kg of glucose was infused to keep glucose levels stable during the insulin infusion. As a result, the study actually demonstrated the combined effect of exogenous insulin and glucose on cerebral glucose uptake. This effect may be exerted either through a metabolic effect of insulin on brain glucose uptake or through a neuronal activation produced by the combined glucose-insulin infusion.
Another approach that has been taken to introduce insulin into the brain is intranasal administration. Experimental studies using mice (Gizurarson et al., 1995) , rats (Thome, et al., 2004) or monkeys (Anand et al., 1974 . Gopinath et al., 1978 showed that peptides delivered into the nasal cavity via, or close to, the olfactory epithelium are transported into the brain within 10 to 15 minutes. Various mechanisms are thought to allow peptides to enter the brain through the intranasal route, although the precise mechanisms have not been elucidated. The mechanism most likely to provide rapid entry into the brain involves an extraneuronal pathway through perineural channels that deliver peptides to the parenchyma and/or the CSF (Frey, 2002 (Kupila et al., 2003) . More-over, no effect on blood glucose levels was found, indicating that intranasal insulin does not induce hypoglycemia.
A study examined the effect of 20IU of insulin administered in the nasal cavities every 15 min for 2.5 h in adult male volunteers of normal weight (Kern et al., 1999 (Kern et al., 1990 . Tamburrano et al., 1988 ).
The results of these studies suggest that insulin itself is the cause of the observed neuroelectric changes. Another study used the hyperinsulinemic/ euglycemic clamp to study the effect of low and high levels of blood insulin on evoked brain potentials, as well as on neuropsychological performance (Kern et al., 2001 ). The results revealed no difference between the N1 and P2 components elicited during the presentation of frequent tones under low and high insulin levels. An increase in P3 latency at the frontal and parietal placement was observed but, contrary to the intranasal study, no clear baseline-to-peak P3 amplitude increase. There was an increase in slow wave in the frontal regions during the high insulin condition and a small increase in the number of emotional and food-related words recalled toward the end of the 6 h of testing, which was concurrent with an increase of correct responses during the interference condition of the Stroop test and increases in the feeling of hunger.
Lastly, an experiment examined the effect of 8 weeks of intranasal insulin on cognitive performance and mood (Benedict et al., 2004) . A 40IU insulin dose was infused into the nose 4 times a day. The participants were first tested during the placebo phase of the trial, after the infusion of the first insulin solution, and week before the end of the trial. No difference was found between the per-formance of the insulin and saline groups for memory, except for delayed recall of words tested week after the last testing session. Furthermore, no effect of insulin on the Stroop test or on word stem completion was found.
There were, however, increases in the self-rating mood scores for self-confidence and well-being, as well as a reduced self-rating of depression after receiving insulin for 8 weeks (Benedict et (Juul, 2003) . Insulin, IGF-I, and IGF-II each has its own receptor but cross-interact with low affinity with each others' receptors. In blood, insulin is found in picomolar concentrations whereas IGF-I is found in nanomolar concentrations. In theory, this would lead to a much higher impact of IGF-I on all three receptors if not for the finding that much of the IGF is bound to IGF binding proteins in the blood, which blocks its biological activity (Baxter et al., 1998) .
Both IGF-I and IGFBP-3 decrease monotonically after puberty (Juul et al., 1994 (Mustafa et al., 1999) .
Also, IDDM and severe insulin resistance may cause acquired IGF-I resistance through a decrease in IGF-I availability or altered second messenger systems (Jain et al., 1998) . Studies in patients with diabetes have shown that in insulin-deficient states, serum IGF-I concentrations are low and increase with insulin therapy (Bereket et al., 1996) . Although total IGF-I has been found to be within normal values in type 2 diabetes, free IGF-I remains elevated in type 2 diabetic patients to a degree similar to that observed in obese individuals without diabetes (Frystyk et al., 1999) . In normal subjects, low IGF-I is associated with high 2-h glucose concentrations during a glucose tolerance test (Sandhu et al., 2002) , indicating that IGF-I has a role in peripheral uptake of glucose.
Studies conducted in experimental animals have shown that if IGF-I synthesis by the liver is stopped, the animals become insulin-resistant, and this situation is improved when IGF-I is administered. Likewise, deletion of the IGF-I receptor in muscle tissue in mice induces severe insulin resistance. The administration of IGF-I to patients with type 2 diabetes mellitus has been shown to result in an improvement in insulin sensitivity and a reduction in the requirement for exogenously administered insulin to maintain glucose homeostasis (Clemmons, 2004) .
In summary, IGF-I is involved in brain development and maturation. Peripheral levels are associated with peripheral glucose regulation and interact with insulin mechanisms that control glucose disposal. In the next section, we briefly review the results of studies that have examined the impact of insulin and IGF-I on amyloid production and disposal in animal models and in patients with Alzheimer's disease.
INSULIN AND IGF-I AND AMYLOID ACCUMULATION
Beta-amyloid (AI3) is a potemially deleterious compound when it accumulates in the aging brain and is associated with Alzheimer's disease (Selkoe, 2001) . During aging, IGF-I levels decline, with a decreased sensitivity to insulin and IGF-I as well (Jain et al., 1998 (Carro et al., 2002) , and protecting from its toxic effects (Niikura et al., 2001) .
Previous experiments had shown an increased uptake of insulin at the blood brain barrier of the Tg2576 (double transgenic APP and PSI) mouse (Poduslo et al., 2001 ) and when fed a highcholesterol diet for 7 weeks, an increased amyloid load and deposit size in the Tg2576 mouse (Refolo et al., 2000) . In a more recent experiment, Tg2576 mice were given access to a 60% fat diet and it was found that the diet induced insulin resistance, higher weight, and higher evoked blood glucose levels, but no change in total cholesterol occurred compared with standard-chow-fed animals (Ho et al., 2004) . However, a 5-month exposure to the diet doubled the amount of AI3-40 and AI342 and also increased the number and volume of 6E10-immunopositive amyloid plaques. The high-fat diet also reduced markers of insulin receptor activity (PI3K, AKT/PKB, and Glycogen synthase kinase-3. ), consistent with insulin resistance and reduced performance in the water maze. Finally, the high-fat diet also reduced IDE expression and activity.
On the other hand, the inhibition of GSK-3t by lithium chloride has been shown to decrease the production of amyloid peptides in animal models of Alzheimer's disease (Phiel et (Shiiki et al., 2004) .
Another experiment using hippocampal cell cultures showed that treatment with insulin produced an increase in IDE-protein levels, which was accompanied by an increase in phosphadylinositol-3 (PI-3) . The inhibition of PI-3 abolished the upregulation of IDE by insulin, suggesting that the effect of insulin on IDE may be mediated through an activation of the insulin receptor. The authors also showed that in Tg2576 mice raised on a safflower oil-based diet, a reduction in IDE mRNA and protein expression correlated with the level of beta-amyloid in the hippocampus.
Finally, a post-mortem study showed reduced IDE levels in the hippocampus and temporal cortex of Alzheimer's patients, and the highest reductions were found in patients with two copies of the ApoE4 allele . Additionally, levels of IDE and neprilysin were found to be lower in the human hippocampus and cortex compared with levels in the cerebellum, a structure having fewer amyloid deposits in AD (Caccamo et al., 2005 
